Literature DB >> 19261830

Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.

Dana Rizk1, Claudine Jurkovitz, Emir Veledar, Susan Bagby, Deborah A Baumgarten, Frederic Rahbari-Oskoui, Theodore Steinman, Arlene B Chapman.   

Abstract

BACKGROUND AND OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited progressive disorder associated with significant pain and discomfort affecting quality of life. This study determined the impact of pain medication use and other clinical, biochemical and genetic characteristics on the physical and mental well being of predialysis ADPKD patients using the Short Form 36 (SF-36) questionnaire. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The authors prospectively evaluated ADPKD patients in the Cohort Study, funded by the Polycystic Kidney Disease Foundation. Data on clinical, biochemical, and radiologic variables were collected in patients who were given the Short Form-36 questionnaire. Variables independently associated with the Physical Component Summary (PCS) and the Mental Component Summary (MCS) scores were identified.
RESULTS: One hundred fifty-two patients had a mean PCS and MCS of 46.9 +/- 11.3 and 51.0 +/- 9.0, similar to the general population and better than the ESRD population. Eleven (7%) reported pain medication intake within 1 mo of evaluation and demonstrated lower PCS than those not taking pain medications. Patients with GFR >or= 80 ml/min/1.73 m(2) had greater PCS than those with GFR < 80 ml/min/1.73 m(2). Age, BMI, pulse pressure, pain medication use, and education level independently associate with PCS and account for 32% of the variability of the measurement. Pulse pressure correlated with MCS.
CONCLUSIONS: Predialysis ADPKD patients assess their quality of life similar to the general population. Age, BMI, pulse pressure, pain medication intake, and education level link to their physical well-being.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261830      PMCID: PMC2653655          DOI: 10.2215/CJN.02410508

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  24 in total

1.  Investigating correlates of health related quality of life in a low-income sample of patients with diabetes.

Authors:  F Camacho; R T Anderson; R A Bell; D C Goff; V Duren-Winfield; D D Doss; R Balkrishnan
Journal:  Qual Life Res       Date:  2002-12       Impact factor: 4.147

2.  Increased systolic pressure in chronic uremia. Role of arterial wave reflections.

Authors:  G London; A Guerin; B Pannier; S Marchais; A Benetos; M Safar
Journal:  Hypertension       Date:  1992-07       Impact factor: 10.190

Review 3.  Pain management in polycystic kidney disease.

Authors:  Z H Bajwa; S Gupta; C A Warfield; T I Steinman
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

4.  Health-related quality of life in Australian adults with renal insufficiency: a population-based study.

Authors:  Fiona Y F Chow; Esther M Briganti; Peter G Kerr; Steven J Chadban; Paul Z Zimmet; Robert C Atkins
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

5.  Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Antonio Alberto Lopes; Jennifer L Bragg-Gresham; Sudtida Satayathum; Keith McCullough; Trinh Pifer; David A Goodkin; Donna L Mapes; Eric W Young; Robert A Wolfe; Philip J Held; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

6.  Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients.

Authors:  E Levine; J J Grantham
Journal:  AJR Am J Roentgenol       Date:  1992-07       Impact factor: 3.959

7.  Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Authors:  Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Kyongtae T Bae; Deborah A Baumgarten; Philip J Kenney; Bernard F King; James F Glockner; Louis H Wetzel; Marijn E Brummer; W Charles O'Neill; Michelle L Robbin; William M Bennett; Saulo Klahr; Gladys H Hirschman; Paul L Kimmel; Paul A Thompson; J Philip Miller
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

8.  Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients.

Authors:  Edmund G Lowrie; Roberta Braun Curtin; Nancy LePain; Dorian Schatell
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

9.  Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.

Authors:  Robert Schrier; Kimberly McFann; Ann Johnson; Arlene Chapman; Charles Edelstein; Godela Brosnahan; Tevfik Ecder; Lyn Tison
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

10.  Impact of socioeconomic status on the quality of life of ESRD patients.

Authors:  Ricardo Sesso; João F Rodrigues-Neto; Marcos B Ferraz
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

View more
  26 in total

1.  Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease.

Authors:  Miklos Z Molnar; Lilia R Lukowsky; Elani Streja; Ramanath Dukkipati; Jennie Jing; Allen R Nissenson; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Hypertens       Date:  2010-12       Impact factor: 4.844

2.  The relationship between liver cyst volume and QOL in Japanese ADPKD patients.

Authors:  Satoru Muto; Masahiko Ando; Saori Nishio; Kazushige Hanaoka; Yoshifumi Ubara; Ichiei Narita; Kouichi Kamura; Toshio Mochizuki; Ken Tsuchiya; Kazuhiko Tsuruya; Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2019-12-26       Impact factor: 2.801

Review 3.  Evaluation and management of pain in autosomal dominant polycystic kidney disease.

Authors:  Marie C Hogan; Suzanne M Norby
Journal:  Adv Chronic Kidney Dis       Date:  2010-05       Impact factor: 3.620

4.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

5.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; James E Bost; Vicente E Torres; Lisa Guay-Woodford; Kyongtae Ty Bae; Douglas Landsittel; Jie Li; Bernard F King; Diego Martin; Louis H Wetzel; Mark E Lockhart; Peter C Harris; Marva Moxey-Mims; Mike Flessner; William M Bennett; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

6.  Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease.

Authors:  Lilia R Lukowsky; Miklos Z Molnar; Joshua J Zaritsky; John J Sim; Istvan Mucsi; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2011-12-29       Impact factor: 5.992

Review 7.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

8.  Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.

Authors:  Debbie S Gipson; Howard Trachtman; Frederick J Kaskel; Milena K Radeva; Jennifer Gassman; Tom H Greene; Marva M Moxey-Mims; Ronald J Hogg; Sandra L Watkins; Richard N Fine; John P Middleton; V M Vehaskari; Susan L Hogan; Suzzane Vento; Patti A Flynn; Leslie M Powell; June L McMahan; Norman Siegel; Aaron L Friedman
Journal:  Kidney Int       Date:  2010-12-22       Impact factor: 10.612

Review 9.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

10.  Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Authors:  Kevin F Erickson; Glenn M Chertow; Jeremy D Goldhaber-Fiebert
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.